CD38单抗-话题@MedSci

#CD38单抗#

11篇内容 | 1798人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2233824, encodeId=69562233824d7, content=<a href='/topic/show?id=adf8290261f' target=_blank style='color:#2F92EE;'>#免疫性血小板减少症#</a> <a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a> <a href='/topic/show?id=3f0d120e34d1' target=_blank style='color:#2F92EE;'>#CM313#</a>, objectTitle=NEJM：一种CD38单抗CM313有望用于治疗免疫性血小板减少症, objectType=article, longId=849013, objectId=dbc584901326, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241023/16e127336ad5427e80b1a01376a1c4bf-C4qoBSc6eUEf.jpg, objectUrl=/article/show_article.do?id=dbc584901326, replyNumber=0, likeNumber=18, createdTime=2024-10-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=dbc584901326, moduleTitle=NEJM：一种CD38单抗CM313有望用于治疗免疫性血小板减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbc584901326)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208238, encodeId=633b220823867, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=ASCO 2024：新诊断多发性骨髓瘤新突破，CD38单抗Isatuximab与VRd联用显著改善无进展生存期（IMROZ 3期研究）, objectType=article, longId=828446, objectId=f86b82844696, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240604/1717482390146_1608702.jpg, objectUrl=/article/show_article.do?id=f86b82844696, replyNumber=0, likeNumber=110, createdTime=2024-06-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f86b82844696, moduleTitle=ASCO 2024：新诊断多发性骨髓瘤新突破，CD38单抗Isatuximab与VRd联用显著改善无进展生存期（IMROZ 3期研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f86b82844696)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1253559, encodeId=3c5a1253559a5, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=一例CD38单抗对输血相容性检测的影响, objectType=article, longId=734170, objectId=b0e7e341708c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0e7e341708c, replyNumber=0, likeNumber=80, createdTime=2022-08-03, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0e7e341708c, moduleTitle=一例CD38单抗对输血相容性检测的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0e7e341708c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253558, encodeId=7ef01253558ed, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=英国NICE积极推荐将赛诺菲的CD38单抗Sarclisa，用于治疗复发/难治性多发性骨髓瘤, objectType=article, longId=202215, objectId=ec9a2022152a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9a2022152a, replyNumber=0, likeNumber=70, createdTime=2020-10-18, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9a2022152a, moduleTitle=英国NICE积极推荐将赛诺菲的CD38单抗Sarclisa，用于治疗复发/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9a2022152a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253557, encodeId=7591125355ef1, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, objectType=article, longId=199783, objectId=eb8f199e83c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb8f199e83c9, replyNumber=0, likeNumber=101, createdTime=2020-08-23, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb8f199e83c9, moduleTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb8f199e83c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253556, encodeId=9b07125355685, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, objectType=article, longId=194121, objectId=ec9d1941215a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9d1941215a, replyNumber=0, likeNumber=58, createdTime=2020-05-15, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9d1941215a, moduleTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9d1941215a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253555, encodeId=3d3c1253555f4, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, objectType=article, longId=188065, objectId=7e7c18806539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7c18806539, replyNumber=0, likeNumber=65, createdTime=2020-02-16, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7c18806539, moduleTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e7c18806539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253554, encodeId=54621253554df, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, objectType=article, longId=180138, objectId=16d3180138ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d3180138ee, replyNumber=0, likeNumber=63, createdTime=2019-09-29, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d3180138ee, moduleTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d3180138ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253553, encodeId=ab4b1253553df, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤, objectType=article, longId=175459, objectId=e3f31e5459bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3f31e5459bb, replyNumber=0, likeNumber=79, createdTime=2019-07-16, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3f31e5459bb, moduleTitle=强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3f31e5459bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253552, encodeId=cdb712535529b, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, objectType=article, longId=167615, objectId=3d4d16e61584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4d16e61584, replyNumber=0, likeNumber=83, createdTime=2019-06-05, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4d16e61584, moduleTitle=2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d4d16e61584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253551, encodeId=44d9125355117, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=Blood：联合新一代CD38单抗与免疫调节药物有望更好的抑制复发性骨髓瘤, objectType=article, longId=103526, objectId=94cf103526e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94cf103526e1, replyNumber=0, likeNumber=78, createdTime=2017-06-28, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94cf103526e1, moduleTitle=Blood：联合新一代CD38单抗与免疫调节药物有望更好的抑制复发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94cf103526e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1253550, encodeId=6602125355068, content=<a href='/topic/show?id=5a3943193a' target=_blank style='color:#2F92EE;'>#CD38单抗#</a>, objectTitle=J Immunol：CD38单抗Daratumumab能够引发FcR介导的细胞程序性死亡, objectType=article, longId=71459, objectId=a558e14596b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a558e14596b, replyNumber=0, likeNumber=0, createdTime=2016-06-24, rootId=0, userName=fangcong, userId=b79433, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a558e14596b, moduleTitle=J Immunol：CD38单抗Daratumumab能够引发FcR介导的细胞程序性死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a558e14596b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD38单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#免疫性血小板减少症# #CD38单抗# #CM313#

NEJM：一种CD38单抗CM313有望用于治疗免疫性血小板减少症

2024-10-29发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #CD38单抗#

ASCO 2024：新诊断多发性骨髓瘤新突破，CD38单抗Isatuximab与VRd联用显著改善无进展生存期（IMROZ 3期研究）

2024-06-04发表于上海

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

一例CD38单抗对输血相容性检测的影响

2022-08-03

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

英国NICE积极推荐将赛诺菲的CD38单抗Sarclisa，用于治疗复发/难治性多发性骨髓瘤

2020-10-18

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤

2020-08-23

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险

2020-05-15

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤

2020-02-16

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤

2019-09-29

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤

2019-07-16

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

2019 ASCO：Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人

2019-06-05

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

Blood：联合新一代CD38单抗与免疫调节药物有望更好的抑制复发性骨髓瘤

2017-06-28

fangcong (审核中...)

前往app查看评论内容

#CD38单抗#

J Immunol：CD38单抗Daratumumab能够引发FcR介导的细胞程序性死亡

2016-06-24

科室
- - 订阅+
  - 更多科室
工具
服务